Form 4: Director Scheiner Granted SpyGlass Pharma Options

SpyGlass Pharma Director Zachary Scheiner was granted 27,400 stock options with a $16 exercise price, vesting monthly over three years.

Summary

• Zachary Scheiner, a Director and 10% Owner of SpyGlass Pharma, Inc. (SGP), was granted 27,400 stock options.
• The options have an exercise price of $16 per share.
• The grant date for these options is February 5, 2026, and they are set to expire on February 5, 2036.
• Vesting occurs monthly, with one thirty-sixth (1/36th) of the shares vesting each month following the grant date, contingent on Scheiner's continued service as an Outside Director.
• Scheiner disclaims beneficial ownership of the options and underlying common stock, as they are held for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., with proceeds offsetting advisory fees owed to RA Capital Management, L.P.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued alignment of a key director's interests with shareholder value and is a standard practice for director compensation.

Positives

• The grant of stock options to a director aligns management's interests with long-term shareholder value, as the options gain value if the stock price increases above the exercise price.
• The three-year monthly vesting schedule encourages long-term commitment from the director.

Negatives

• The future exercise of these options could lead to a slight dilution of existing shareholders if new shares are issued.

Risks

• The vesting of the options is contingent on Zachary Scheiner's continued service as an Outside Director, meaning unvested options would be forfeited if his directorship ceases.

Future Outlook

The vesting schedule indicates a three-year commitment period for the director to fully realize the equity grant, aligning with long-term strategic goals.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation to attract and retain experienced board members. This grant to a director who is also associated with a significant institutional investor (RA Capital) further strengthens the alignment between the company's governance and its major financial backers.

Comparison to Industry Standards

• The grant of 27,400 options to a director is within the typical range for early-stage or mid-cap biotech companies, comparable to grants seen at companies like Akero Therapeutics or Structure Therapeutics for non-executive directors, though the specific value depends on the company's market capitalization and stage of development.
• A 10-year option term and a three-year monthly vesting schedule are common structures designed to incentivize long-term commitment and performance, aligning with best practices observed in the broader life sciences sector.

Corporate Governance

Related Party Transactions

• Zachary Scheiner holds the option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P., and is obligated to turn over net proceeds to RA Capital Management, L.P. to offset advisory fees. This indicates a relationship between the director, the company, and RA Capital entities.

Stakeholder Impact

• Shareholders: Potential for slight dilution upon option exercise, but also increased alignment of a director's interests with shareholder value.
• Employees: No direct impact mentioned, but the existence of an Equity Incentive Plan suggests a broader framework for employee equity.
• RA Capital Management, L.P. (and associated funds): Will benefit from the option's value, offsetting advisory fees, indicating a strong financial interest in SpyGlass Pharma's performance.

Next Steps

• Continued service of Zachary Scheiner as an Outside Director for the options to vest.
• Potential exercise of vested stock options by the reporting person or RA Capital Management, L.P. in the future.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a director, which is a standard compensation practice and generally viewed as a neutral to slightly positive event for aligning interests. It does not provide new fundamental information about the company's operations or financial performance that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

SpyGlass Pharma, SGP, Zachary Scheiner, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Incentive Plan, RA Capital Management